Ryo Honda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ryo Honda has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Kazuo Kuwata
United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan
6 shared publications Teiko Komori Nomura
Gifu University
6 shared publicationsKazuo Kuwata
United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan; Department of Gene and Development, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan
4 shared publications- Kazuki Heishima
The United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Gifu, Japan
3 shared publications - Tatsushi Nakayama
Department of Pharmacy Gifu Pharmaceutical University Gifu Japan
3 shared publications - Bunji Uno
Faculty of Pharmacy, Gifu University of Medical Science, 4-3-3 Nijigaoka, Kani, Gifu 509-0923, Japan
2 shared publications
Latest Publications
- 20 August 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (9) , 2639-2653
Thermal Stability, Plasma Pharmacokinetics, and Tumor Response Modeling of a Cell-Penetrating Protein That Cleaves RAS Family GTPases
RRSP–RBD–TAT is a cell-penetrating fusion protein composed of a RAS/Rap1-specific endopeptidase (RRSP), a RAS-binding domain (RBD), and a transactivator-of-transcription (TAT) cell-permeable peptide. It catalytically and irreversibly cleaves RAS family proteins and has shown potent antitumor activity. To advance this unconventional intracellular protein therapeutic toward translation, we characterized its thermal stability, developed a capillary-based Simple Western immunoassay for quantitative blood analysis, measured plasma pharmacokinetics and tumor-associated exposure, and linked these measurements to intratumoral signaling and tumor response. RRSP–RBD–TAT retained its secondary structure and anticancer activity for 3 days at 20–37 °C, whereas temperatures above approximately 50 °C caused rapid unfolding, aggregation, and irreversible loss of activity. The Simple Western assay separated immunoreactive RRSP–RBD–TAT from the albumin-rich region of serum and plasma, enabling quantitative concentration–time profiling after intravenous administration. Following a single 50 mg/kg dose, plasma concentrations declined rapidly with a biexponential profile, whereas apparent micromolar tumor-associated concentrations were detected at 3 and 6 h. Tumors showed near-complete depletion of intact RAS and prolonged suppression of ERK phosphorylation, which persisted after tumor-associated drug levels had declined below the practical detection range. An integrated semimechanistic pharmacokinetic–pharmacodynamic–tumor growth inhibition model reproduced the observed dose-dependent responses. Exploratory human-scaled simulations revealed dose- and schedule-dependent effects and suggested that both improved intracellular potency and prolonged systemic persistence could lower the projected effective dose, with potency enhancement producing the larger shift under the current model assumptions.
- 20 August 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (9) , 2639-2653
Thermal Stability, Plasma Pharmacokinetics, and Tumor Response Modeling of a Cell-Penetrating Protein That Cleaves RAS Family GTPases
RRSP–RBD–TAT is a cell-penetrating fusion protein composed of a RAS/Rap1-specific endopeptidase (RRSP), a RAS-binding domain (RBD), and a transactivator-of-transcription (TAT) cell-permeable peptide. It catalytically and irreversibly cleaves RAS family proteins and has shown potent antitumor activity. To advance this unconventional intracellular protein therapeutic toward translation, we characterized its thermal stability, developed a capillary-based Simple Western immunoassay for quantitative blood analysis, measured plasma pharmacokinetics and tumor-associated exposure, and linked these measurements to intratumoral signaling and tumor response. RRSP–RBD–TAT retained its secondary structure and anticancer activity for 3 days at 20–37 °C, whereas temperatures above approximately 50 °C caused rapid unfolding, aggregation, and irreversible loss of activity. The Simple Western assay separated immunoreactive RRSP–RBD–TAT from the albumin-rich region of serum and plasma, enabling quantitative concentration–time profiling after intravenous administration. Following a single 50 mg/kg dose, plasma concentrations declined rapidly with a biexponential profile, whereas apparent micromolar tumor-associated concentrations were detected at 3 and 6 h. Tumors showed near-complete depletion of intact RAS and prolonged suppression of ERK phosphorylation, which persisted after tumor-associated drug levels had declined below the practical detection range. An integrated semimechanistic pharmacokinetic–pharmacodynamic–tumor growth inhibition model reproduced the observed dose-dependent responses. Exploratory human-scaled simulations revealed dose- and schedule-dependent effects and suggested that both improved intracellular potency and prolonged systemic persistence could lower the projected effective dose, with potency enhancement producing the larger shift under the current model assumptions.
- Open Access
- 6 August 2026
- Published by Wiley in Cancer Science
Daraxonrasib and Beyond: Pan‐ RAS Inhibition, Resistance, and Next‐Generation Strategies
RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins. In the randomized phase III RASolute 302 trial, daraxonrasib substantially improved survival over chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma while maintaining manageable toxicity, thereby establishing a clinically useful therapeutic window for pan‐RAS inhibition. Nevertheless, epithelial toxicity and acquired resistance, including mutations affecting ternary‐complex formation and mechanisms associated with increased KRAS abundance, remain important challenges. This review discusses the mechanistic and clinical development of daraxonrasib and examines emerging strategies designed to improve the depth, durability, and selectivity of RAS suppression. These include pan‐KRAS inhibitors, targeted RAS degraders, RAS‐cleaving protein biologics, and tumor‐directed delivery systems. Together, these approaches may reshape the treatment of RAS‐driven cancers across tumor types and disease stages.
- 6 August 2026
- Published by Wiley in Cancer Science
Open AccessDaraxonrasib and Beyond: Pan‐ RAS Inhibition, Resistance, and Next‐Generation Strategies
RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins. In the randomized phase III RASolute 302 trial, daraxonrasib substantially improved survival over chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma while maintaining manageable toxicity, thereby establishing a clinically useful therapeutic window for pan‐RAS inhibition. Nevertheless, epithelial toxicity and acquired resistance, including mutations affecting ternary‐complex formation and mechanisms associated with increased KRAS abundance, remain important challenges. This review discusses the mechanistic and clinical development of daraxonrasib and examines emerging strategies designed to improve the depth, durability, and selectivity of RAS suppression. These include pan‐KRAS inhibitors, targeted RAS degraders, RAS‐cleaving protein biologics, and tumor‐directed delivery systems. Together, these approaches may reshape the treatment of RAS‐driven cancers across tumor types and disease stages.
- Open Access
- 16 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Protein-based pan-RAS inhibitor induces tumor regression in female mice via IFNγ and CD8+ T cell-dependent tumor necrosis
Mutations in K/H/N-RAS occur in approximately 30% of human cancers, yet most RAS mutants remain undruggable in clinical settings. Here, we describe a protein-based pan-RAS inhibitor, RRSP-RBD, that combines a RAS/Rap1A-specific endopeptidase (RRSP) with a RAS-binding domain (RBD). This engineered fusion protein localizes to RAS on the plasma membrane, where it cleaves RAS, disrupts RAS-effector interactions, and effectively inhibits downstream RAS signaling. To achieve intracellular delivery of RRSP-RBD in vivo, we engineer two cell-permeable variants. The diphtheria toxin-based version (RRSP-RBD-DTB) demonstrates femtomolar anti-tumor potency and induces tumor regression in a xenograft mouse model. The cell-permeable peptide-based version (RRSP-RBD-TAT) exhibits robust anti-tumor activity in syngeneic models without inducing irreversible toxicity in normal tissues. Interestingly, anti-tumor efficacy of RRSP-RBD-TAT critically depends on the tumor microenvironment, requiring infiltration by IFNγ + CD8 + T cells to mediate tumor regression. Pharmacokinetic and toxicity evaluations indicate that RRSP-RBD is tolerated under the conditions tested and support further investigation as a protein-based pan-RAS inhibitor (all mouse studies were performed in female mice).
- 16 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessProtein-based pan-RAS inhibitor induces tumor regression in female mice via IFNγ and CD8+ T cell-dependent tumor necrosis
Mutations in K/H/N-RAS occur in approximately 30% of human cancers, yet most RAS mutants remain undruggable in clinical settings. Here, we describe a protein-based pan-RAS inhibitor, RRSP-RBD, that combines a RAS/Rap1A-specific endopeptidase (RRSP) with a RAS-binding domain (RBD). This engineered fusion protein localizes to RAS on the plasma membrane, where it cleaves RAS, disrupts RAS-effector interactions, and effectively inhibits downstream RAS signaling. To achieve intracellular delivery of RRSP-RBD in vivo, we engineer two cell-permeable variants. The diphtheria toxin-based version (RRSP-RBD-DTB) demonstrates femtomolar anti-tumor potency and induces tumor regression in a xenograft mouse model. The cell-permeable peptide-based version (RRSP-RBD-TAT) exhibits robust anti-tumor activity in syngeneic models without inducing irreversible toxicity in normal tissues. Interestingly, anti-tumor efficacy of RRSP-RBD-TAT critically depends on the tumor microenvironment, requiring infiltration by IFNγ + CD8 + T cells to mediate tumor regression. Pharmacokinetic and toxicity evaluations indicate that RRSP-RBD is tolerated under the conditions tested and support further investigation as a protein-based pan-RAS inhibitor (all mouse studies were performed in female mice).
- Open Access
- 23 April 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (10) , 2827-2836
Digenic HNF1A and ABCC8 variants provide mechanistic insight into early-onset diabetes
Context: Oligogenic inheritance in maturity-onset diabetes of the young (MODY) remains poorly characterized, and the contribution of multiple candidate variants to disease pathogenesis is incompletely understood. Objective: To investigate the pathogenicity and mechanistic contribution of multiple MODY gene variants identified in a MODY-like family and determine their role in early-onset diabetes. Methods: Comprehensive genetic analysis of known MODY genes was performed in a MODY-like family. Functional effects of HNF1A and HNF1B variants were assessed using luciferase reporter assays in HEK293T cells. Functional characterization of ABCC8 variants included Kir6.2-dependent thallium (Tl+) flux assays, sulfonylurea responsiveness, and channel stability. Results: Four variants in 3 MODY genes were identified in the proband: novel HNF1A p.Ser551Lysfs*2, HNF1B p.Glu102Ala, and ABCC8 p.Arg298Cys and p.Arg521Gln. Functional analysis showed that HNF1A p.Ser551Lysfs*2 retained approximately 5% of wild-type transactivation activity, consistent with loss-of-function, whereas HNF1B p.Glu102Ala and ABCC8 p.Arg521Gln exhibited wild-type–like function. In contrast, ABCC8 p.Arg298Cys reduced channel activity to 77% of wild-type levels while preserving sulfonylurea responsiveness. Segregation analysis identified HNF1A p.Ser551Lysfs*2 and ABCC8 p.Arg298Cys in affected parents. The proband, who inherited both pathogenic variants, developed diabetes earlier than either parent and was exposed to maternal hyperglycemia in utero, which may also have contributed to this early onset. Conclusion: Functional characterization distinguishes pathogenic from variants of unknown significance and supports digenic inheritance of HNF1A and ABCC8. Their additive effects, together with intrauterine hyperglycemia, likely accelerated disease onset. This study provides mechanistic evidence for oligogenic contributions to MODY and expands the genetic architecture of early-onset diabetes.
- 23 April 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (10) , 2827-2836
Open AccessDigenic HNF1A and ABCC8 variants provide mechanistic insight into early-onset diabetes
Context: Oligogenic inheritance in maturity-onset diabetes of the young (MODY) remains poorly characterized, and the contribution of multiple candidate variants to disease pathogenesis is incompletely understood. Objective: To investigate the pathogenicity and mechanistic contribution of multiple MODY gene variants identified in a MODY-like family and determine their role in early-onset diabetes. Methods: Comprehensive genetic analysis of known MODY genes was performed in a MODY-like family. Functional effects of HNF1A and HNF1B variants were assessed using luciferase reporter assays in HEK293T cells. Functional characterization of ABCC8 variants included Kir6.2-dependent thallium (Tl+) flux assays, sulfonylurea responsiveness, and channel stability. Results: Four variants in 3 MODY genes were identified in the proband: novel HNF1A p.Ser551Lysfs*2, HNF1B p.Glu102Ala, and ABCC8 p.Arg298Cys and p.Arg521Gln. Functional analysis showed that HNF1A p.Ser551Lysfs*2 retained approximately 5% of wild-type transactivation activity, consistent with loss-of-function, whereas HNF1B p.Glu102Ala and ABCC8 p.Arg521Gln exhibited wild-type–like function. In contrast, ABCC8 p.Arg298Cys reduced channel activity to 77% of wild-type levels while preserving sulfonylurea responsiveness. Segregation analysis identified HNF1A p.Ser551Lysfs*2 and ABCC8 p.Arg298Cys in affected parents. The proband, who inherited both pathogenic variants, developed diabetes earlier than either parent and was exposed to maternal hyperglycemia in utero, which may also have contributed to this early onset. Conclusion: Functional characterization distinguishes pathogenic from variants of unknown significance and supports digenic inheritance of HNF1A and ABCC8. Their additive effects, together with intrauterine hyperglycemia, likely accelerated disease onset. This study provides mechanistic evidence for oligogenic contributions to MODY and expands the genetic architecture of early-onset diabetes.
- Open Access
- 8 October 2024
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 13 (1) , 1-5
Ultrasensitive detection of TDP-43 and amyloid-β protein aggregates using micelle-assisted seed amplification assay
- 8 October 2024
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 13 (1) , 1-5
Open AccessUltrasensitive detection of TDP-43 and amyloid-β protein aggregates using micelle-assisted seed amplification assay
- Open Access
- 4 July 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-11
ARL-17477 is a dual inhibitor of NOS1 and the autophagic-lysosomal system that prevents tumor growth in vitro and in vivo
ARL-17477 is a selective neuronal nitric oxide synthase (NOS1) inhibitor that has been used in many preclinical studies since its initial discovery in the 1990s. In the present study, we demonstrate that ARL-17477 exhibits a NOS1-independent pharmacological activity that involves inhibition of the autophagy-lysosomal system and prevents cancer growth in vitro and in vivo. Initially, we screened a chemical compound library for potential anticancer agents, and identified ARL-17477 with micromolar anticancer activity against a wide spectrum of cancers, preferentially affecting cancer stem-like cells and KRAS-mutant cancer cells. Interestingly, ARL-17477 also affected NOS1-knockout cells, suggesting the existence of a NOS1-independent anticancer mechanism. Analysis of cell signals and death markers revealed that LC3B-II, p62, and GABARAP-II protein levels were significantly increased by ARL-17477. Furthermore, ARL-17477 had a chemical structure similar to that of chloroquine, suggesting the inhibition of autophagic flux at the level of lysosomal fusion as an underlying anticancer mechanism. Consistently, ARL-17477 induced lysosomal membrane permeabilization, impaired protein aggregate clearance, and activated transcription factor EB and lysosomal biogenesis. Furthermore, in vivo ARL-17477 inhibited the tumor growth of KRAS-mutant cancer. Thus, ARL-17477 is a dual inhibitor of NOS1 and the autophagy-lysosomal system that could potentially be used as a cancer therapeutic.
- 4 July 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-11
Open AccessARL-17477 is a dual inhibitor of NOS1 and the autophagic-lysosomal system that prevents tumor growth in vitro and in vivo
ARL-17477 is a selective neuronal nitric oxide synthase (NOS1) inhibitor that has been used in many preclinical studies since its initial discovery in the 1990s. In the present study, we demonstrate that ARL-17477 exhibits a NOS1-independent pharmacological activity that involves inhibition of the autophagy-lysosomal system and prevents cancer growth in vitro and in vivo. Initially, we screened a chemical compound library for potential anticancer agents, and identified ARL-17477 with micromolar anticancer activity against a wide spectrum of cancers, preferentially affecting cancer stem-like cells and KRAS-mutant cancer cells. Interestingly, ARL-17477 also affected NOS1-knockout cells, suggesting the existence of a NOS1-independent anticancer mechanism. Analysis of cell signals and death markers revealed that LC3B-II, p62, and GABARAP-II protein levels were significantly increased by ARL-17477. Furthermore, ARL-17477 had a chemical structure similar to that of chloroquine, suggesting the inhibition of autophagic flux at the level of lysosomal fusion as an underlying anticancer mechanism. Consistently, ARL-17477 induced lysosomal membrane permeabilization, impaired protein aggregate clearance, and activated transcription factor EB and lysosomal biogenesis. Furthermore, in vivo ARL-17477 inhibited the tumor growth of KRAS-mutant cancer. Thus, ARL-17477 is a dual inhibitor of NOS1 and the autophagy-lysosomal system that could potentially be used as a cancer therapeutic.
- Open Access
- 8 February 2022
- Published by MDPI AG in Electrochem
- Vol. 3 (1) , 115-128
Electrochemical and Mechanistic Study of Superoxide Scavenging by Pyrogallol in N,N-Dimethylformamide through Proton-Coupled Electron Transfer
Scavenging of electrogenerated superoxide radical anion (O2•−) by pyrogallol (PyH3) was investigated on the basis of cyclic voltammetry and in situ electrolytic electron spin resonance spectrum in N,N-dimethylformamide with the aid of density functional theory (DFT) calculations. Quasi-reversible dioxygen/O2•− redox couple was modified by the presence of PyH3, suggesting that O2•− was scavenged by PyH3 through proton-coupled electron transfer (PCET) involving two proton transfer and one electron transfer. DFT calculation suggested that the pre-reactive formation of a hydrogen-bond (HB) complex and the subsequent concerted two-proton-coupled electron transfer characterized by catechol moiety in PyH3 is plausible mechanism that embodies the superior kinetics of the O2•− scavenging by PyH3 as shown in the electrochemical results. Furthermore, it was clarified that the three hydroxyl groups of PyH3 promote the formation of HB complex, in comparative analyses using related compounds, resulting in the promotion of the O2•− scavenging.
- 8 February 2022
- Published by MDPI AG in Electrochem
- Vol. 3 (1) , 115-128
Open AccessElectrochemical and Mechanistic Study of Superoxide Scavenging by Pyrogallol in N,N-Dimethylformamide through Proton-Coupled Electron Transfer
Scavenging of electrogenerated superoxide radical anion (O2•−) by pyrogallol (PyH3) was investigated on the basis of cyclic voltammetry and in situ electrolytic electron spin resonance spectrum in N,N-dimethylformamide with the aid of density functional theory (DFT) calculations. Quasi-reversible dioxygen/O2•− redox couple was modified by the presence of PyH3, suggesting that O2•− was scavenged by PyH3 through proton-coupled electron transfer (PCET) involving two proton transfer and one electron transfer. DFT calculation suggested that the pre-reactive formation of a hydrogen-bond (HB) complex and the subsequent concerted two-proton-coupled electron transfer characterized by catechol moiety in PyH3 is plausible mechanism that embodies the superior kinetics of the O2•− scavenging by PyH3 as shown in the electrochemical results. Furthermore, it was clarified that the three hydroxyl groups of PyH3 promote the formation of HB complex, in comparative analyses using related compounds, resulting in the promotion of the O2•− scavenging.
- Open Access
- 22 December 2021
- Published by MDPI AG in Antioxidants
- Vol. 11 (1) , 9
Electrochemical and Mechanistic Study of Reactivities of α-, β-, γ-, and δ-Tocopherol toward Electrogenerated Superoxide in N,N-Dimethylformamide through Proton-Coupled Electron Transfer
Scavenging of superoxide radical anion (O2•−) by tocopherols (TOH) and related compounds was investigated on the basis of cyclic voltammetry and in situ electrolytic electron spin resonance spectrum in N,N-dimethylformamide (DMF) with the aid of density functional theory (DFT) calculations. Quasi-reversible dioxygen/O2•− redox was modified by the presence of TOH, suggesting that the electrogenerated O2•− was scavenged by α-, β-, γ-TOH through proton-coupled electron transfer (PCET), but not by δ-TOH. The reactivities of α-, β-, γ-, and δ-TOH toward O2•− characterized by the methyl group on the 6-chromanol ring was experimentally confirmed, where the methyl group promotes the PCET mechanism. Furthermore, comparative analyses using some related compounds suggested that the para-oxygen-atom in the 6-chromanol ring is required for a successful electron transfer (ET) to O2•− through the PCET. The electrochemical and DFT results in dehydrated DMF suggested that the PCET mechanism involves the preceding proton transfer (PT) forming a hydroperoxyl radical, followed by a PCET (intermolecular ET–PT). The O2•− scavenging by TOH proceeds efficiently along the PCET mechanism involving one ET and two PTs.
- 22 December 2021
- Published by MDPI AG in Antioxidants
- Vol. 11 (1) , 9
Open AccessElectrochemical and Mechanistic Study of Reactivities of α-, β-, γ-, and δ-Tocopherol toward Electrogenerated Superoxide in N,N-Dimethylformamide through Proton-Coupled Electron Transfer
Scavenging of superoxide radical anion (O2•−) by tocopherols (TOH) and related compounds was investigated on the basis of cyclic voltammetry and in situ electrolytic electron spin resonance spectrum in N,N-dimethylformamide (DMF) with the aid of density functional theory (DFT) calculations. Quasi-reversible dioxygen/O2•− redox was modified by the presence of TOH, suggesting that the electrogenerated O2•− was scavenged by α-, β-, γ-TOH through proton-coupled electron transfer (PCET), but not by δ-TOH. The reactivities of α-, β-, γ-, and δ-TOH toward O2•− characterized by the methyl group on the 6-chromanol ring was experimentally confirmed, where the methyl group promotes the PCET mechanism. Furthermore, comparative analyses using some related compounds suggested that the para-oxygen-atom in the 6-chromanol ring is required for a successful electron transfer (ET) to O2•− through the PCET. The electrochemical and DFT results in dehydrated DMF suggested that the PCET mechanism involves the preceding proton transfer (PT) forming a hydroperoxyl radical, followed by a PCET (intermolecular ET–PT). The O2•− scavenging by TOH proceeds efficiently along the PCET mechanism involving one ET and two PTs.
- 1 November 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (11) , 1581-1589.e6
Specific inhibition of oncogenic RAS using cell-permeable RAS-binding domains
- 1 November 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (11) , 1581-1589.e6
Specific inhibition of oncogenic RAS using cell-permeable RAS-binding domains
- Open Access
- 25 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21) , 11484
Kaempferol Has Potent Protective and Antifibrillogenic Effects for α-Synuclein Neurotoxicity In Vitro
Aggregation of α-synuclein (α-Syn) is implicated in the pathogenesis of Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Therefore, the removal of α-Syn aggregation could lead to the development of many new therapeutic agents for neurodegenerative diseases. In the present study, we succeeded in generating a new α-Syn stably expressing cell line using a piggyBac transposon system to investigate the neuroprotective effect of the flavonoid kaempferol on α-Syn toxicity. We found that kaempferol provided significant protection against α-Syn-related neurotoxicity. Furthermore, kaempferol induced autophagy through an increase in the biogenesis of lysosomes by inducing the expression of transcription factor EB and reducing the accumulation of α-Syn; thus, kaempferol prevented neuronal cell death. Moreover, kaempferol directly blocked the amyloid fibril formation of α-Syn. These results support the therapeutic potential of kaempferol in diseases such as synucleinopathies that are characterized by α-Syn aggregates.
- 25 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21) , 11484
Open AccessKaempferol Has Potent Protective and Antifibrillogenic Effects for α-Synuclein Neurotoxicity In Vitro
Aggregation of α-synuclein (α-Syn) is implicated in the pathogenesis of Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Therefore, the removal of α-Syn aggregation could lead to the development of many new therapeutic agents for neurodegenerative diseases. In the present study, we succeeded in generating a new α-Syn stably expressing cell line using a piggyBac transposon system to investigate the neuroprotective effect of the flavonoid kaempferol on α-Syn toxicity. We found that kaempferol provided significant protection against α-Syn-related neurotoxicity. Furthermore, kaempferol induced autophagy through an increase in the biogenesis of lysosomes by inducing the expression of transcription factor EB and reducing the accumulation of α-Syn; thus, kaempferol prevented neuronal cell death. Moreover, kaempferol directly blocked the amyloid fibril formation of α-Syn. These results support the therapeutic potential of kaempferol in diseases such as synucleinopathies that are characterized by α-Syn aggregates.